Alps Advisors Inc. Has $367,000 Stock Position in Bruker Co. (NASDAQ:BRKR)

Alps Advisors Inc. decreased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 17.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 8,351 shares of the medical research company’s stock after selling 1,721 shares during the period. Alps Advisors Inc.’s holdings in Bruker were worth $367,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in Bruker by 0.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,691,185 shares of the medical research company’s stock worth $1,483,075,000 after buying an additional 180,171 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Bruker by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 10,866,673 shares of the medical research company’s stock valued at $542,789,000 after buying an additional 156,591 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Bruker by 1.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,335,079 shares of the medical research company’s stock valued at $166,587,000 after buying an additional 36,643 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Bruker by 1.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,924,095 shares of the medical research company’s stock valued at $96,109,000 after buying an additional 22,812 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Bruker by 2,436.8% in the 2nd quarter. Invesco Ltd. now owns 1,698,456 shares of the medical research company’s stock valued at $84,838,000 after buying an additional 1,631,502 shares during the last quarter. Institutional investors and hedge funds own 66.63% of the company’s stock.

BRKR opened at $49.17 on Friday. Bruker Co. has a 1-year low of $26.10 and a 1-year high of $52.23. The stock’s fifty day simple moving average is $45.11 and its 200 day simple moving average is $44.53. The company has a current ratio of 2.23, a quick ratio of 1.32 and a debt-to-equity ratio of 0.67. The stock has a market cap of $7.41 billion, a PE ratio of 35.12, a price-to-earnings-growth ratio of 2.36 and a beta of 1.36.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, October 31st. The medical research company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.05. Bruker had a return on equity of 28.02% and a net margin of 10.20%. The business had revenue of $521.10 million for the quarter, compared to analysts’ expectations of $493.52 million. During the same quarter in the prior year, the business earned $0.37 EPS. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. Equities analysts forecast that Bruker Co. will post 1.62 earnings per share for the current year.

Several equities research analysts have recently commented on the company. ValuEngine raised Bruker from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Bank of America raised Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Thursday, September 26th. Stifel Nicolaus assumed coverage on Bruker in a report on Thursday. They issued a “hold” rating for the company. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Zacks Investment Research downgraded Bruker from a “hold” rating to a “sell” rating and set a $46.00 price objective for the company. in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company’s stock. Bruker currently has a consensus rating of “Hold” and an average price target of $50.70.

In other Bruker news, Director Marc A. Kastner sold 3,203 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $47.39, for a total transaction of $151,790.17. Following the transaction, the director now owns 7,608 shares in the company, valued at approximately $360,543.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Munch sold 47,203 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $42.87, for a total value of $2,023,592.61. Following the transaction, the vice president now owns 96,063 shares in the company, valued at approximately $4,118,220.81. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,108 shares of company stock worth $2,849,941. 26.50% of the stock is owned by company insiders.

Bruker Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Recommended Story: Operating Income

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit